Navigation Links
Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
Date:9/1/2008

ith other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

On site at ESC in Munich

Natacha Gassenbach

(508) 250-9348 (mobile)

Media Relations

Boston Scientific

Geraldine Varoqui'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
2. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
3. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
4. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
5. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
6. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
7. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
10. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
11. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... This webinar will examine the ... promotion, and review the basic FDA regulations and ... apply these principles through real world case studies ... fundamentals on FDA regulations and guidance related to ...     Assessing traditional and newer forms of promotional materials ...
(Date:6/18/2013)... THE WOODLANDS, Texas , June 18, 2013 ... LXRX ), a biopharmaceutical company focused on ... that John Northcott has joined the ... strategy, and operations. Mr. Northcott brings extensive commercial ... on-market commercialization across a variety of therapeutic areas. ...
(Date:6/18/2013)... Though health care jobs continued to be added ... Labor Statistics -- the increase was far below the calendar ... care jobs were added in home health care and outpatient ... jobs. Overall, the U.S. unemployment rate stayed flat at 7.6 ... that a total of just over 36,000 job cuts were ...
(Date:6/18/2013)... 18, 2013 PathoGenetix, Inc. ... for rapid bacterial strain typing, announced today that ... company as Vice President of Engineering. Dr. Luckey ... company’s RESOLUTION™ Microbial Genotyping System . The ... instrument, pathogen-specific assay kits, database and software, will ...
Breaking Biology Technology:Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 2MedZilla Employment Report for June 2013 -- Jobs in Health Care Grow, But at Slower Pace 3PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 2PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 3
... March 21, 2011 ICAP Ocean Tomo ... medicinal nebulizer on March 31st at the ICAP Ocean ... The technology of this patent portfolio provides improvements to ... Recent technological advancements have triggered the use ...
... 2011 Reportlinker.com announces that a new market ... Global Nanobiotechnology Industry ... the worldwide markets for Nanobiotechnology in US$ Million ... Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes ...
... VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused ... (TLR8) agonists and antagonists for the treatment of ... presentation of positive clinical results from its randomized, ... of allergic rhinitis. The results demonstrated statistically significant ...
Cached Biology Technology:ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air 2ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air 3ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air 4Reportlinker Adds Global Nanobiotechnology Industry 2Reportlinker Adds Global Nanobiotechnology Industry 3Reportlinker Adds Global Nanobiotechnology Industry 4Reportlinker Adds Global Nanobiotechnology Industry 5Reportlinker Adds Global Nanobiotechnology Industry 6Reportlinker Adds Global Nanobiotechnology Industry 7Reportlinker Adds Global Nanobiotechnology Industry 8Reportlinker Adds Global Nanobiotechnology Industry 9Reportlinker Adds Global Nanobiotechnology Industry 10Reportlinker Adds Global Nanobiotechnology Industry 11Reportlinker Adds Global Nanobiotechnology Industry 12Reportlinker Adds Global Nanobiotechnology Industry 13Reportlinker Adds Global Nanobiotechnology Industry 14Reportlinker Adds Global Nanobiotechnology Industry 15Reportlinker Adds Global Nanobiotechnology Industry 16Reportlinker Adds Global Nanobiotechnology Industry 17VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting 2
(Date:6/17/2013)... 17, 2013How kids eat their food may turn out to ... a new study out of St. Michael,s Hospital. , ... found a significant association between poor eating habits in ... or "bad" cholesterol, putting them at risk for ... in the Canadian Medical Association Journal today. ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
(Date:6/17/2013)... bacteria, and algae, is a common component of sugar-free ... the medical field it,s approved by the FDA ... used during surgery as a substance that opens the ... , Now Profs. Ehud Gazit and Daniel Segal of ... and the Sagol School of Neuroscience, along with their ...
Breaking Biology News(10 mins):Poor eating behaviors may put preschoolers at risk for later health problems 2'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Artificial sweetener a potential treatment for Parkinson's disease 2
... of antibiotics that followed it, streptococcus bacteria have remained ... reason: the superb evolutionary skills of this pathogen to ... published this week in Science , scientists from ... genome sequencing to identify the precise steps in the ...
... for its immunosuppressive functions could also point the way ... the Indiana University School of Medicine have reported. ... enzyme called SHP2, which plays an important role in ... mutations are also known to cause several types of ...
... This release is available in German . ... mammals. As defense against these herbivores they developed complex defense ... and a number of toxic chemical substances. For decades it ... incurs costs to the plants. Now, using a new method ...
Cached Biology News:New research traces evolutionary path of multidrug-resistant strep bacteria 2New research traces evolutionary path of multidrug-resistant strep bacteria 3
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
... an aqueous-based mounting medium designed for ... Gel/Mount is especially recommended when using ... FluoroBlue. It can also be used ... fluorescein (FITC), Rhodamine (TMRITC) and Texas ...
... Reagent A - Fixation medium Reagent B ... intended for fixing cells in suspension with ... with Reagent B. This procedure gives antibodies ... morphological scatter characteristics of the cells intact. ...
...
Biology Products: